Logo

American Heart Association

  8
  0


Final ID: LBP29

Iatrogenic Vessel Dissection during Neuroendovascular treatment: Results of Japanese registry of Neuroendovascular Therapy 4 (JR-NET4)

Abstract Body: Objective:
Iatrogenic vessel dissection (IVD) is an infrequent complication of neuroendovascular therapy. However, differences in risk among disease, patient characteristics, procedures, or treatment conditions remain unclear, and the effect of IVD on patient outcomes is yet to be determined.

Methods:
The Japanese Registry of Neuroendovascular Therapy (JR-NET) 4 database comprises interventional neuroradiology procedures conducted in Japan between 2015 and 2019. We present a retrospective analysis utilizing JR-NET 4 to verify the factors associated with IVD and evaluate their impact on outcomes. There were eight treatment interventions in which IVD cases could be detected and analyzed. We compared the patients’ baseline characteristics, including age, sex, and pre-treatment modified Rankin Scale (mRS), as well as treatment environments such as etiology, anesthesia methods, and detailed therapeutic approaches, between the groups with and without IVD complications. Furthermore, we examined the 30-day mRS of the two groups.

Results:
The total number of treatments used in the analysis was 54,297. The incidence of IVD in all endovascular treatment was 0.64%. The treatments with significantly higher rates of IVD were intracranial percutaneous transluminal angioplasty with or without stenting (PTA/PTAS) (3.2%) , extracranial PTA/PTAS (1.5%), and endovascular treatment for acute ischemic stroke (0.92%). Although the most frequently registered treatment was for cerebral aneurysms (22,406 cases) with an incidence rate of 0.45% for IVD, treatments under local anesthesia with sedation and treatments of flow diverters showed a significantly higher incidence of IVD (p<0.001, p=0.013). Clinical outcome across all treatments, the proportion of patients with modified Rankin Scale (mRS) 5-6 was significantly higher in the IVD group. IVD on aneurysm treatment was associated with mRS 5-6 outcome at 30days: odds ratio=2.9 (95% CI, 1.18-6.43); p=0.013, whereas carotid artery stenting was not: odds ratio=3.97 (95% CI, 0.60-15.3); p=0.079.

Conclusion:
This analysis showed that the incidence of IVD varies depending on the treatment, and that the impact on prognosis also varies.
  • Sasaki, Natsuhi  ( Japanese Red Cross Fukui Hospital , Fukui , Japan )
  • Ishii, Akira  ( Juntendo University , Tokyo , Japan )
  • Imamura, Hirotoshi  ( National Cerebral and Cardiovascular Center , Suita , Japan )
  • Satow, Tetsu  ( Kindai University , Sayama , Japan )
  • Sakai, Chiaki  ( Kyoto University , Kyoto-city , Japan )
  • Iihara, Koji  ( National Cerebral and Cardiovascular Center , Suita , Japan )
  • Yoshimura, Shinichi  ( Hyogo Medical University , Nishinomiya , Japan )
  • Matsumaru, Yuji  ( University of Tsukuba , Ibaraki , Japan )
  • Sakai, Nobuyuki  ( Seijinkai Shimizu Hospital , Kyoto , Japan )
  • Author Disclosures:
    Natsuhi Sasaki: DO NOT have relevant financial relationships | Akira Ishii: DO have relevant financial relationships ; Speaker:Medtronic:Active (exists now) ; Consultant:Terumo Neuro:Active (exists now) ; Speaker:Asahi Intec:Active (exists now) ; Speaker:Johnson and Johnson:Active (exists now) ; Speaker:Kaneka:Active (exists now) ; Speaker:Terumo:Active (exists now) ; Speaker:Stryker:Active (exists now) | Hirotoshi Imamura: No Answer | Tetsu Satow: No Answer | CHIAKI SAKAI: No Answer | Koji Iihara: No Answer | Shinichi Yoshimura: DO have relevant financial relationships ; Speaker:Daiichi Sankyo:Past (completed) ; Speaker:Tokai Medical:Past (completed) ; Speaker:Eisai:Past (completed) ; Speaker:Nxera Pharma:Past (completed) ; Speaker:Medicos Hirata:Past (completed) ; Speaker:Terumo:Past (completed) ; Speaker:Kaneka Medics:Past (completed) ; Speaker:Johnson & Johnson:Past (completed) ; Speaker:Medtronic:Past (completed) ; Speaker:Stryker:Past (completed) ; Speaker:Otsuka Pharmaceutical:Past (completed) ; Speaker:Bristol-Meyers Squibb:Past (completed) ; Speaker:Bayer:Past (completed) ; Speaker:Pfizer:Past (completed) ; Speaker:Shionogi:Past (completed) | Yuji Matsumaru: DO have relevant financial relationships ; Individual Stocks/Stock Options:Epsilon Medical:Active (exists now) ; Executive Role:Epsilon Medical:Active (exists now) | Nobuyuki Sakai: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Late-Breaking Science Posters

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
Autoimmunity and Sex Inform Clinical Outcomes of Non-Aortic Arterial Dissections

Gonzalez Moret Yurilu, Chacin Suarez Audry, Musri M. Carolina, Yanamandala Mounica, Lo Kevin, Loscalzo Joseph, Gerhard-herman Marie, Pandey Arvind

Carotid Artery Assessment via Blood Acoustic Signatures Captured by a Wearable Seismometer Patch

Sang Brian, Desai Nia, Park Jin-woo, Junek Greg, Wen Haoran, Fonseca Michael, Kvantaliani Nino, Nahab Fadi, Ayazi Farrokh

More abstracts from these authors:
Bioresorbable Magnesium Flow Diverter that Promotes Neointimal Formation in Aneurysmal Necks: Animal Experiments

Matsukawa So, Sakurai Shinichi, Iwasaki Kiyotaka, Arakawa Yoshiki, Ishii Akira, Akiyama Ryo, Sasaki Natsuhi, Nishi Hidehisa, Chihara Hideo, Hayashi Tomoko, Kawamura Yoshihito, Yagi Shinichi

Pathological and Clinical Findings of Calcified Nodules in Carotid Artery Stenosis

Yamada Kiyofumi, Hatakeyama Kinta, Amemiya Kisaki, Abe Soichiro, Shirakawa Manabu, Imamura Hirotoshi, Iihara Koji, Yoshimura Shinichi, Kataoka Hiroharu

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)